Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
72 65 79 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
66 54 78 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 1 promise resolved, 5 needed for a score.
All types combined: 71 (likely 64 to 77, high confidence), from 79 claims: 60 factual claims, 19 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Balaji Srinivasan's claims
“And so this is going to be a gigantic shot in the arm for every diagnostic company in the world, every medical imaging company.”
Balaji Srinivasan, podcast guest 13 March 2020 #78 Balaji Srinivasan: Exploring COVID-19 — The Knowledge Project (HappyScribe)
The pandemic will be a gigantic boost for every diagnostic and medical imaging company in the world, with defense-budget-level spending.
Mostly true True in substance, wrong in a detail.
The second judge would not resolve this claim; the verdict shown is the first judge's.
What would count as true or false
Horizon: end-2021. The claim has two parts: diagnostic companies and medical-imaging companies, worldwide, each getting a 'gigantic' boost, with spending at the scale of defence budgets. TRUE: diagnostic companies broadly (e.g. Abbott, Roche Diagnostics, Thermo Fisher, Quidel, Hologic, BGI) and imaging companies broadly (e.g. Siemens Healthineers, GE Healthcare, Philips, Canon Medical) show large pandemic-driven gains in revenue or market value in 2020–2021 according to company filings, and government spending on testing reached tens of billions of dollars or more. MOSTLY TRUE: both sectors gained substantially, but the boost was smaller than 'gigantic' for one of them, or spending fell somewhat short of defence-budget scale. MIXED: one sector, typically diagnostics, got a gigantic boost while the other was flat or hurt, for example because elective imaging procedures were deferred. MOSTLY FALSE: only a narrow subset of companies (e.g. COVID test makers) benefited, while most diagnostics and imaging companies did not. FALSE: neither sector saw meaningful pandemic-driven gains.
Evidence
- Roche's 2021 test sales collect on COVID demand, base business ... Fierce Biotech · 3 February 2022
“Combined, Roche said its testing sales grew 29% to 17.8 billion Swiss francs, or about $19.4 billion U.S., with COVID-19 diagnostics accounting for about a quarter of the year’s total.”
- Abbott weathers 2021's COVID-testing roller coaster ride ... Fierce Biotech · 26 January 2022
“For the full year, the medtech giant reported total COVID test sales of $7.7 billion.”
- [PDF] Annual Financial Report - Siemens - Digital Asset Management Siemens AG
“Markets addressed by the imaging business grew significantly, mainly due to large COVID 19-driven demand for computer tomography systems and initial signs of normalization in all other modalities.”
- Quidel, Hologic, other test stocks sink as vaccine result brings hope for pandemic's end MedTech Dive · 10 November 2020
“COVID-19 has fueled meteoric growth at companies that serve the coronavirus testing market.”
Reasoning
The diagnostics side is well supported. Roche's testing sales grew 29% in 2021 to CHF 17.8 billion, with COVID-19 tests about a quarter of the total (E1). Abbott reported $7.7 billion in COVID test sales for 2021 (E2), and MedTech Dive described "meteoric growth" at companies serving the testing market (E4). For imaging, Siemens' FY2021 report says the markets its imaging business serves grew significantly, mainly because of COVID-driven demand for CT systems (E3). However, that is one company rather than the sector broadly, and no evidence shows government testing spending at defence-budget scale. So the claim mostly holds, but the imaging and spending parts are not fully shown.
Cite this claim
Balaji Srinivasan, “The pandemic will be a gigantic boost for every diagnostic and medical imaging company in the world, with defense-budget-level spending.” (said 13 March 2020). Verdict: mostly true. Reliability API, claim c_778a5661d489, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_778a5661d489
Claims without a verdict
- Unresolvable 148
- Not yet due 21
- Own records only 2
- Not researched 227
- Not checkable 1,091
Is a verdict here wrong, or do you speak for Balaji Srinivasan? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.